Abstract Context The European Association of Urology (EAU) Renal Cell Carcinoma (RCC)
Guideline Panel has prepared evidence-based guidelines and recommendations for the …

The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …

PURPOSE To provide recommendations for the management of patients with metastatic
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …

Abstract Context The European Association of Urology Renal Cell Carcinoma (RCC)
Guideline Panel has prepared evidence-based guidelines and recommendations for the …

Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned
from a nonspecific immune approach (in the cytokine era), to targeted therapy against …

Kidney cancer accounts for 5% and 3% of all adult malignancies in men and women,
respectively, thus representing the 7th most common cancer in men, and the 10th most …

Background Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR,
and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of …

Background Treatment for renal cell carcinoma has been revolutionised by inhibitors of
VEGF receptor. Previous studies have suggested that treatment with a VEGF receptor …

Context There have been substantial changes in the management of patients with metastatic
renal cell carcinoma (mRCC) over the past decade, with upfront immunotherapy-based …

Purpose Following curative treatment for localised renal cell carcinoma (RCC), up to 30% of
patients develop tumour recurrence. Prognostic scores are essential to guide individualised …